New model aims to predict and prevent deadly transplant complication
NCT ID NCT07588945
First seen May 19, 2026 · Last updated May 19, 2026
Summary
This study tests whether giving the drug ruxolitinib early can prevent severe graft-versus-host disease (GvHD) in adults receiving a stem cell transplant from a half-matched donor. The trial uses a special model (daGOAT) to identify patients at highest risk. About 438 participants will be enrolled, and the main goal is to see if this approach reduces severe GvHD within the first 100 days after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT-RELATED DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.